News

GSK under fire in fraud case
Enlarge image

Regulatory AffairsUK

GSK under fire in fraud case

04.07.2012 - GSK has been fined a record $3bn for drug fraud. The UK-based company admitted it had made inappropriate hospitality offerings to bribe physicians.

The pharma giant invited health care practitioners to enjoy deep-sea fishing, hot air balloon rides and golfing days in Hawaii. The company hoped the practice would mean doctors would prescribe more of their drugs. The case, described as "unprecedented in both size and scope" by deputy US attorney general James Cole, included allegations that GSK promoted two drugs for unapproved uses and failed to report safety data about a diabetes drug to the Food and Drug Administration (FDA).

Problems were first flagged up in 2001, when a whistle blower sparked internal investigations within the company. An official investigation begun by the US Attorney's office of Colorado in 2004 and was later taken over by the US Attorney's Office of Massachusetts. With its admission of guilt, GSK agreed to pay $1bn in criminal fines and forfeits and additional $2bn to settle civil claims. "Whilst these originate in a different era for the company, they cannot and will not be ignored", stated Andrew Witty, Glaxosmithkline chief executive, adding that the company has fundamentally changed its procedures for compliance, marketing and selling to avoid further misbehaviour.

http://www.european-biotechnology-news.com/news/news/2012-03/gsk-under-fire-in-fraud-case.html

BusinessGermany

24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.

BusinessUK

20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.

BusinessEUGermanyUK

15.08.2014 Some of Europe’s biggest pharma companies are competing in a bidding war for US biotech Intermune Inc., Bloomberg reports, citing insider reports as the source.

ResearchEUGermanyUK

13.08.2014 The Ebola epidemic is still raging on in West Africa and thus far there is

neither vaccine nor cure for the viral disease. The only flickers of hope:

an experimental antibody serum and an early-stage vaccine.

BusinessFrance

11.08.2014 Will Sanofi succeed where Pfizer failed? The French pharmaceutical company has taken on the commercialisation of Mannkind Corporation’s inhaled insulin product Afrezza.

ResearchSwedenGermany

08.08.2014 Boehringer Ingelheim is walking away from Swedish Orexo's prostaglandin inhibition project OX-MPI. Germany's largest researching pharmaceutical company had been responsible for the project's research and development since 2005.

ResearchSwitzerlandDenmark

06.08.2014 Roche is re-expanding its involvement in RNAi technologies. The Swiss pharmaceutical company will pay up to €335m for the acquisition of the Danish company Santaris Pharma A/S.

ResearchUKSwitzerland

03.08.2014 In its efforts to become the leading country in genetic research, the UK has attracted investments worth more than £300m (€376m) to map 100,000 human genomes by 2017.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • EVOTEC3.94 EUR8.54%
  • VITA 343.90 EUR4.00%
  • SANTHERA86.50 CHF3.59%

FLOP

  • WILEX2.30 EUR-2.54%
  • 4SC1.22 EUR-2.40%
  • ADDEX3.99 CHF-1.97%

TOP

  • SANTHERA86.50 CHF32.1%
  • BB BIOTECH144.50 EUR9.3%
  • BASILEA103.90 CHF4.4%

FLOP

  • WILEX2.30 EUR-17.9%
  • MOLOGEN7.84 EUR-17.5%
  • 4SC1.22 EUR-14.1%

TOP

  • SANTHERA86.50 CHF3831.8%
  • CO.DON2.57 EUR221.2%
  • PAION2.46 EUR182.8%

FLOP

  • CYTOS0.26 CHF-93.5%
  • MEDIGENE4.55 EUR-66.9%
  • THERAMETRICS0.08 CHF-42.9%

No liability assumed, Date: 27.08.2014